Download Sample
Add to CartGlobal Acute Ischemic Stroke Diagnosis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Diagnostic Type;
Computed Tomography, Magnetic Resonance Imaging, Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography, and Other Diagnostic Types.By Surgery Type;
Carotid Endarterectomy, Angioplasty, and Endovascular Mechanical Thrombectomy.By Treatment;
Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Acute Ischemic Stroke Diagnosis Market (USD Million), 2021 - 2031
In the year 2024, the Global Acute Ischemic Stroke Diagnosis Market was valued at USD 2,232.78 million. The size of this market is expected to increase to USD 3,413.84 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.1%.
The global acute ischemic stroke diagnosis market is rapidly expanding due to the increasing incidence of ischemic strokes worldwide and the advancements in diagnostic technologies. Acute ischemic stroke occurs when there is a blockage in the blood vessels supplying blood to the brain, which can lead to permanent brain damage if not identified and treated quickly. Early and accurate diagnosis is crucial for effective intervention and treatment, which has driven the demand for improved diagnostic tools. The market includes various diagnostic technologies such as imaging techniques, biomarkers, and diagnostic tools that help healthcare professionals assess the condition and determine the most appropriate course of action for patients.
The rise in risk factors, such as aging populations, high prevalence of lifestyle diseases like hypertension, diabetes, and obesity, and a growing awareness of stroke symptoms, has contributed significantly to the market growth. Advances in imaging technologies, including magnetic resonance imaging (MRI) and computed tomography (CT) scans, have improved the ability to detect ischemic strokes early, enabling faster treatment. Additionally, developments in point-of-care diagnostics and the incorporation of artificial intelligence (AI) in diagnostic tools are enhancing the speed and accuracy of stroke diagnosis, leading to better patient outcomes.
As the demand for effective stroke management and early diagnosis increases, healthcare providers are adopting advanced technologies to improve diagnostic accuracy and treatment timelines. The market is also witnessing innovations in the development of novel biomarkers that could assist in diagnosing ischemic stroke at the molecular level, offering more personalized treatment options. Furthermore, the global push for better healthcare infrastructure, particularly in developing regions, is expected to drive the adoption of advanced diagnostic technologies, expanding the market for acute ischemic stroke diagnosis across various regions.
Global Acute Ischemic Stroke Diagnosis Market Recent Developments
-
In July 2021, Siemens Healthineers announced the Food and Drug Administration (FDA) clearance of the MAGNETOM Free.Max, a new High,V magnetic resonance (MR) scanner that combines a 0.55 Tesla (0.55T) field strength with deep learning technologies and advanced image processing.
-
In March 2021, C,Path announced the launch of a collaborative acute kidney injury project with the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, the Office of Translational Science, and the Division of Cardiology and Nephrology. This initiative aims to develop a suite of prognostic tools to enhance the detection of drug,induced kidney injury
Segment Analysis
The Global Acute Ischemic Stroke Diagnosis Market is segmented by diagnostic type, with key modalities including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography (ECG), Echocardiography, and other diagnostic techniques. CT and MRI remain the most widely used imaging techniques due to their accuracy in detecting stroke-related brain abnormalities, while Carotid Ultrasound helps assess blood flow in the carotid arteries. Cerebral Angiography is considered the gold standard for visualizing blockages in cerebral blood vessels, whereas ECG and Echocardiography are critical in detecting underlying heart conditions that may lead to ischemic stroke.
In terms of surgery type, the market includes Carotid Endarterectomy, Angioplasty, and Endovascular Mechanical Thrombectomy. Carotid Endarterectomy is a conventional surgical procedure used to remove plaque buildup in the carotid arteries, reducing the risk of stroke. Angioplasty involves the insertion of a balloon catheter to open narrowed arteries, often accompanied by stenting. Endovascular Mechanical Thrombectomy has gained traction as a minimally invasive procedure that uses specialized devices to remove blood clots directly from blocked brain arteries, significantly improving patient outcomes when performed promptly.
The treatment segment covers Tissue Plasminogen Activator (tPA), Anticoagulants, Antiplatelets, and Antihypertensives. tPA is the only FDA-approved thrombolytic therapy for acute ischemic stroke, effectively dissolving clots when administered within a critical time window. Anticoagulants, such as heparin and warfarin, help prevent clot formation, while Antiplatelets, including aspirin and clopidogrel, reduce platelet aggregation and lower the risk of recurrent strokes. Antihypertensive medications play a crucial role in stroke prevention by managing high blood pressure, a major risk factor for ischemic stroke.
Geographically, the market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America dominates the market due to advanced healthcare infrastructure, high awareness, and strong reimbursement policies, particularly in the U.S. and Canada. Europe follows closely, benefiting from well-established stroke care programs and rising adoption of advanced diagnostic technologies. The Asia Pacific region is expected to witness the fastest growth, driven by increasing stroke incidence, improving healthcare facilities, and government initiatives in countries like China, India, and Japan. The Middle East & Africa and Latin America regions are gradually expanding due to rising investments in healthcare infrastructure and growing awareness about stroke diagnosis and treatment.
Global Acute Ischemic Stroke Diagnosis Segment Analysis
In this report, the Global Acute Ischemic Stroke Diagnosis Market has been segmented by Diagnostic Type, Surgery Type, Treatment and Geography.
Global Acute Ischemic Stroke Diagnosis Market, Segmentation by Diagnostic Type
The Global Acute Ischemic Stroke Diagnosis Market has been segmented by Diagnostic Type into Computed Tomography, Magnetic Resonance Imaging, Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Other Diagnostic Types.
The Global Acute Ischemic Stroke Diagnosis Market is segmented based on diagnostic type, with each modality playing a crucial role in early detection and treatment planning. Computed Tomography (CT) is one of the most widely used imaging techniques due to its speed and accessibility. CT scans help identify ischemic strokes by detecting brain tissue damage and ruling out hemorrhagic strokes, ensuring prompt medical intervention. The introduction of advanced CT imaging technologies, such as CT perfusion and CT angiography, has further enhanced diagnostic accuracy, making this modality a key contributor to market growth.
Magnetic Resonance Imaging (MRI) is another essential diagnostic tool in the acute ischemic stroke diagnosis market. MRI provides high-resolution images of brain tissue, allowing for a more detailed assessment of stroke-related damage compared to CT scans. It is particularly useful for detecting small infarcts and distinguishing between acute and chronic strokes. The growing adoption of diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) in MRI has significantly improved early stroke detection, driving demand for this segment. However, the high cost and limited availability of MRI scanners in certain regions may pose challenges to widespread adoption.
Carotid Ultrasound, Cerebral Angiography, Electrocardiography (ECG), and Echocardiography are also vital components of stroke diagnosis. Carotid ultrasound helps assess carotid artery stenosis, a major risk factor for ischemic stroke, while cerebral angiography provides detailed visualization of cerebral blood vessels to identify blockages. ECG and echocardiography play a crucial role in detecting underlying cardiac conditions such as atrial fibrillation, which increases stroke risk. Technological advancements in these diagnostic tools, such as portable ultrasound devices and AI-driven ECG analysis, are expected to enhance their effectiveness and adoption rates.
Lastly, the Other Diagnostic Types category encompasses emerging and specialized diagnostic approaches, including blood biomarkers and transcranial Doppler ultrasound. Blood-based tests are gaining attention for their potential to provide rapid stroke diagnosis by identifying biomarkers associated with ischemic events. Similarly, transcranial Doppler ultrasound offers real-time assessment of cerebral blood flow, aiding in stroke risk evaluation and monitoring. The increasing focus on point-of-care diagnostics and precision medicine is likely to drive innovation in this segment, further expanding the scope of acute ischemic stroke diagnosis worldwide.
Global Acute Ischemic Stroke Diagnosis Market, Segmentation by Surgery Type
The Global Acute Ischemic Stroke Diagnosis Market has been segmented by Surgery Type into Carotid Endarterectomy, Angioplasty, and Endovascular Mechanical Thrombectomy.
The Global Acute Ischemic Stroke Diagnosis Market is segmented based on surgery type, with key categories including Carotid Endarterectomy, Angioplasty, and Endovascular Mechanical Thrombectomy. Each of these surgical interventions plays a crucial role in restoring blood flow to the brain, reducing the risk of long-term complications, and improving patient outcomes. The segmentation helps in understanding the market trends, demand patterns, and technological advancements driving growth in each segment.
Carotid Endarterectomy is a surgical procedure aimed at removing plaque buildup from the carotid arteries to prevent stroke recurrence. This segment is significant due to its established effectiveness in patients with severe carotid artery stenosis. Advancements in surgical techniques and the increasing prevalence of atherosclerosis contribute to the growth of this segment. However, the procedure is generally recommended for specific patient populations, limiting its overall market share compared to less invasive alternatives.
Angioplasty, often accompanied by stenting, is a minimally invasive procedure that involves using a balloon catheter to widen narrowed or blocked arteries. The segment is gaining traction due to its lower risk, shorter recovery time, and growing preference for non-surgical treatment options. The rising adoption of advanced imaging technologies and bioresorbable stents further enhances the market potential for angioplasty. Increased awareness, coupled with the growing burden of cardiovascular diseases, is expected to drive the demand for this segment.
The Endovascular Mechanical Thrombectomy segment is witnessing rapid growth, primarily due to its efficacy in treating large vessel occlusions. This procedure involves the use of specialized devices to physically remove blood clots, significantly improving patient survival and neurological outcomes. Innovations in thrombectomy devices, along with increasing clinical evidence supporting their effectiveness, are fueling market expansion. With the rising incidence of acute ischemic strokes and increasing healthcare investments, this segment is poised for substantial growth in the coming years.
Global Acute Ischemic Stroke Diagnosis Market, Segmentation by Treatment
The Global Acute Ischemic Stroke Diagnosis Market has been segmented by Treatment into Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive.
The Tissue Plasminogen Activator (tPA) segment is a key component of the Global Acute Ischemic Stroke Diagnosis Market, as it is the only FDA-approved thrombolytic therapy for treating acute ischemic stroke. tPA works by dissolving the clot obstructing the blood flow to the brain, helping to restore circulation and minimize long-term damage. Its effectiveness within the critical window of 3 to 4.5 hours after stroke onset has driven its adoption in emergency stroke care. The increasing awareness about early diagnosis and treatment of stroke, along with advancements in thrombolytic drug formulations, is expected to support the growth of this segment.
The Anticoagulant segment plays a crucial role in the management of acute ischemic stroke by preventing further clot formation and reducing the risk of recurrent strokes. These drugs, such as heparin and direct oral anticoagulants (DOACs), are often prescribed to patients with atrial fibrillation or other conditions that increase clotting risk. The growing preference for novel anticoagulants due to their improved safety profile and ease of use is contributing to market expansion. Additionally, ongoing research and development efforts focused on enhancing anticoagulant efficacy with minimal bleeding risk are expected to drive innovation within this segment.
The Antiplatelet segment includes medications like aspirin and clopidogrel, which help prevent platelets from clumping together to form clots. These drugs are widely used for both acute treatment and secondary prevention of ischemic stroke, making them a critical component of stroke management. The increasing prevalence of stroke risk factors such as hypertension, diabetes, and high cholesterol has fueled the demand for antiplatelet therapy. Furthermore, the development of combination therapies, where multiple antiplatelet agents are used together for enhanced effectiveness, is further strengthening the growth prospects of this segment.
The Antihypertensive segment is essential in managing stroke patients, as high blood pressure is a major risk factor for ischemic stroke. Antihypertensive drugs such as beta-blockers, ACE inhibitors, and calcium channel blockers help regulate blood pressure, reducing the likelihood of stroke occurrence and recurrence. With the rising global burden of hypertension and its direct correlation with stroke incidence, the demand for effective blood pressure management strategies is growing. Technological advancements in blood pressure monitoring and personalized medicine approaches are further expected to enhance the effectiveness and adoption of antihypertensive treatments in stroke prevention and post-stroke care.
Global Acute Ischemic Stroke Diagnosis Market, Segmentation by Geography
In this report, the Global Acute Ischemic Stroke Diagnosis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Acute Ischemic Stroke Diagnosis Market Share (%), by Geographical Region, 2024
The North American acute ischemic stroke diagnosis market is a dominant player, primarily due to advanced healthcare infrastructure, high awareness levels, and significant government support for stroke-related research and treatment. The presence of key market players and rapid adoption of advanced diagnostic imaging technologies, such as MRI and CT scans, further drive the region's growth. Additionally, an aging population and the rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes, contribute to the increasing demand for accurate and early stroke diagnosis.
Europe follows closely behind, benefiting from well-established healthcare systems, increasing stroke incidences, and strong reimbursement policies for stroke diagnostics. Countries like Germany, the UK, and France lead the market with ongoing research initiatives and the adoption of AI-driven diagnostic tools. Moreover, collaborations between healthcare providers and technology firms are enhancing early detection and treatment efficiency, thereby improving patient outcomes. The European Stroke Organization’s initiatives to standardize and improve stroke care also contribute to the market's growth.
The Asia-Pacific region is witnessing rapid expansion in the acute ischemic stroke diagnosis market, driven by an increasing geriatric population, a growing burden of stroke cases, and improvements in healthcare accessibility. Countries such as China, Japan, and India are investing heavily in medical infrastructure, particularly in neuroimaging technologies. Government initiatives and private-sector investments in telemedicine and AI-assisted stroke diagnosis are further accelerating market growth. However, challenges such as limited stroke awareness and disparities in healthcare access between urban and rural areas remain barriers to full-scale adoption.
In Latin America, the market is expanding at a moderate pace, driven by increasing healthcare investments and improving medical infrastructure. Brazil, Mexico, and Argentina are leading the region in terms of stroke diagnosis advancements, supported by growing awareness campaigns and government-led initiatives for stroke prevention. However, economic constraints, high diagnostic costs, and limited accessibility to advanced imaging technologies in certain areas continue to pose challenges to market growth. Despite these barriers, increasing collaborations between local healthcare providers and international diagnostic technology firms are expected to drive future expansion.
The Middle East and Africa region remains in an early stage of market development, with a growing focus on improving stroke diagnosis and treatment facilities. Countries like the UAE and Saudi Arabia are making significant investments in healthcare modernization, including advanced imaging technology and stroke awareness programs. However, in many African nations, inadequate healthcare infrastructure, a shortage of trained professionals, and financial constraints limit access to timely stroke diagnosis. Efforts by global health organizations and regional governments to enhance stroke care and implement telemedicine solutions may help bridge the gap and stimulate market growth over time.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Acute Ischemic Stroke Diagnosis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities Analysis
Drivers:
- Rising Prevalence of Acute Ischemic Stroke
- Increasing Geriatric Population
-
Advances in Diagnostic Imaging Technologies- Advances in diagnostic imaging technologies serve as a major driver in the global acute ischemic stroke (AIS) diagnosis market by enabling early and accurate detection of stroke events. Cutting-edge imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) have significantly improved the ability to differentiate between ischemic and hemorrhagic strokes, which is crucial for determining the appropriate treatment pathway. Advanced imaging techniques such as diffusion-weighted imaging (DWI) and perfusion imaging (CTP or MRP) help identify the extent of brain tissue damage and ischemic penumbra, allowing for timely interventions like thrombolysis or mechanical thrombectomy.
The integration of artificial intelligence (AI) and machine learning (ML) algorithms into diagnostic imaging has further enhanced stroke detection accuracy and speed. AI-powered imaging tools can rapidly analyze scans, reducing the time required for interpretation by radiologists and improving workflow efficiency in emergency settings. For example, AI-driven automated stroke detection systems can help identify vessel occlusions, assess infarct core volume, and predict patient outcomes, which supports physicians in making faster and more precise treatment decisions. The adoption of cloud-based imaging solutions also allows for remote stroke diagnosis, benefiting healthcare providers in underserved areas.
Technological advancements have led to the development of portable and point-of-care imaging devices, improving access to stroke diagnostics in pre-hospital and rural settings. For instance, mobile stroke units (MSUs) equipped with CT scanners enable real-time stroke assessment in ambulances, significantly reducing the time to treatment initiation. Additionally, the emergence of ultrasound-based transcranial Doppler (TCD) imaging has provided a non-invasive and cost-effective alternative for detecting cerebral blood flow abnormalities, making stroke diagnosis more accessible even in resource-limited regions.
Ongoing research and development (R&D) efforts in imaging contrast agents and hybrid imaging technologies are expected to drive further market growth. Innovations such as multi-modal imaging approaches (combining CT, MRI, and PET) offer comprehensive stroke assessment by integrating anatomical, functional, and molecular data. Additionally, the shift toward personalized medicine has encouraged the development of imaging biomarkers for risk stratification and prognosis prediction in AIS patients. As diagnostic imaging continues to evolve, its role in improving stroke outcomes and expanding the AIS diagnosis market remains critical.
Restraints:
- High Cost of Advanced Diagnostic Procedures
- Limited Accessibility to Healthcare in Developing Regions
-
Stringent Regulatory Approval Processes- The Global Acute Ischemic Stroke (AIS) Diagnosis Market is significantly influenced by stringent regulatory approval processes, which act as a major restraint on market growth. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities enforce strict guidelines to ensure the safety, efficacy, and accuracy of diagnostic technologies. Companies developing AIS diagnostic solutions must undergo extensive clinical trials and validation studies before obtaining regulatory clearance, leading to prolonged product approval timelines and increased costs. These rigorous requirements can delay market entry for innovative diagnostic tools, affecting their commercial viability and patient accessibility.
Another key challenge posed by stringent regulations is the high cost associated with compliance. Companies must invest heavily in clinical studies, documentation, and regulatory submissions to meet the requirements of different markets. For small and mid-sized enterprises, these expenses can be particularly burdensome, limiting their ability to compete with larger, well-established players. Additionally, variations in regulatory frameworks across different regions further complicate the approval process, requiring companies to navigate multiple compliance pathways, thereby delaying international market expansion.
Regulatory scrutiny also extends to post-market surveillance, adding another layer of complexity to the market. Even after gaining approval, diagnostic devices and imaging technologies used for AIS diagnosis must adhere to ongoing reporting requirements, including adverse event monitoring and periodic audits. Failure to meet these post-market obligations can result in product recalls, legal actions, or revocation of approvals, leading to financial losses and reputational damage for manufacturers. This stringent oversight discourages some companies from investing in new AIS diagnostic innovations, slowing down the overall pace of technological advancements.
Despite these challenges, regulatory bodies play a crucial role in maintaining patient safety and ensuring the reliability of diagnostic tools. While compliance may be resource-intensive, it also helps establish trust in new technologies, ultimately benefiting healthcare providers and patients. To overcome regulatory hurdles, companies must adopt strategic approaches such as early engagement with regulatory authorities, leveraging accelerated approval pathways, and investing in regulatory expertise. Streamlining approval processes through regulatory harmonization and fostering collaborations between industry stakeholders and regulators could help reduce delays and support the growth of the Global Acute Ischemic Stroke Diagnosis Market.
Opportunities:
- Technological Advancements in AI-Based Stroke Diagnosis
- Expansion of Telemedicine and Remote Diagnostics
-
Growing Investments in Stroke Research and Development- The global acute ischemic stroke diagnosis market is witnessing significant growth, driven by increasing investments in stroke research and development. Governments, healthcare organizations, and private investors are allocating substantial funds to advance diagnostic technologies, improve treatment outcomes, and enhance stroke management. This rise in funding is fueling innovation in imaging modalities, biomarker identification, and artificial intelligence (AI)-powered diagnostic tools, leading to faster and more accurate stroke detection. Such advancements play a critical role in improving patient prognosis by enabling timely intervention.
Pharmaceutical and biotechnology companies are heavily investing in R&D to develop novel diagnostic approaches and targeted therapies for acute ischemic stroke. Research initiatives are focusing on identifying new biomarkers that can facilitate early diagnosis and differentiation between stroke subtypes. Additionally, advancements in genetic research are contributing to personalized medicine approaches, enabling healthcare providers to tailor stroke treatments based on a patient’s genetic profile. These efforts are expected to expand the scope of diagnostic solutions available in the market, improving overall efficiency and accessibility.
Collaborations and partnerships between academic institutions, research organizations, and industry players are also driving innovation in stroke diagnostics. Funding initiatives from agencies such as the National Institutes of Health (NIH) and the European Stroke Organisation (ESO) are supporting clinical trials and translational research efforts. Moreover, governments in developed and developing economies are increasing grants for stroke-related studies, aiming to reduce the global burden of stroke through early detection and preventive strategies. These joint efforts are accelerating the development of advanced diagnostic tools and expanding their commercial availability.
The rising investments in stroke research are also fostering the integration of emerging technologies such as AI, machine learning, and telemedicine in stroke diagnosis. AI-powered imaging solutions are enhancing the speed and accuracy of stroke detection, while telemedicine platforms are enabling remote diagnosis and consultation, especially in regions with limited access to specialized stroke care. As financial support for stroke research continues to grow, the acute ischemic stroke diagnosis market is expected to witness sustained expansion, benefiting from continuous technological advancements and improved patient outcomes.
Competitive Landscape Analysis
Key players in Global Acute Ischemic Stroke Diagnosis Market include:
- Abbott
- Cardinal Health
- Genentech, Inc.
- Koninklijke Philips N.V.
- Medtronic
- GENERAL ELECTRIC
- Stryker
- Merck & Co., Inc.
- Hitachi High-Tech Corporation
- Boston Scientific Corporation
- Neusoft Corporation
- CANON MEDICAL SYSTEMS CORPORATION
- Teleflex Incorporated
- Bayer AG
- B. Braun SE
- AliveCor India
- Sanofi
- Johnson & Johnson Services, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Diagnostic Type
- Market Snapshot, By Surgery Type
- Market Snapshot, By Treatment
- Market Snapshot, By Region
- Global Acute Ischemic Stroke Diagnosis Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Prevalence of Acute Ischemic Stroke
- Increasing Geriatric Population
- Advances in Diagnostic Imaging Technologies
- Restraints
- High Cost of Advanced Diagnostic Procedures
- Limited Accessibility to Healthcare in Developing Regions
- Stringent Regulatory Approval Processes
- Opportunities
- Technological Advancements in AI-Based Stroke Diagnosis
- Expansion of Telemedicine and Remote Diagnostics
- Growing Investments in Stroke Research and Development
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of New Entrants
- Threat of Substitutes
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Acute Ischemic Stroke Diagnosis Market, By Diagnostic Type, 2021 - 2031 (USD Million)
- Computed Tomography
- Magnetic Resonance Imaging
- Carotid Ultrasound
- Cerebral Angiography
- Electrocardiography
- Echocardiography
- Other Diagnostic Types
- Global Acute Ischemic Stroke Diagnosis Market, By Surgery Type, 2021 - 2031 (USD Million)
- Carotid Endarterectomy
- Angioplasty
- Endovascular Mechanical Thrombectomy
- Global Acute Ischemic Stroke Diagnosis Market, By Treatment, 2021 - 2031 (USD Million)
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- Global Acute Ischemic Stroke Diagnosis Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Acute Ischemic Stroke Diagnosis Market, By Diagnostic Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott
- Cardinal Health
- Genentech, Inc.
- Koninklijke Philips N.V.
- Medtronic
- GENERAL ELECTRIC
- Stryker
- Merck & Co., Inc.
- Hitachi High-Tech Corporation
- Boston Scientific Corporation
- Neusoft Corporation
- CANON MEDICAL SYSTEMS CORPORATION
- Teleflex Incorporated
- Bayer AG
- B. Braun SE
- AliveCor India
- Sanofi
- Johnson & Johnson Services, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market